Oil India Stock Update: Structural
derating, Retain Hold
Oil
India Stock Update: Structural derating; PT revised down to Rs360; Retain Hold.
Ad valorem CESS to relieve OIL now but gains restricted, in case of crude price
recovery: In Union Budget 2016-17, the government has changed the structure of
the cess on oil production from a fixed rate of Rs4,500/metric tonne to ad
valorem (at 20% of crude oil price).
· Tech Mahindra arm’s new IRIS
improves recharge experience in consumers
Tech
Mahindra’s subsidiary Mahindra Comviva has launched IRIS, the newest addition to
its Revenue Plus suite - a monetization platform for CSPs. Comviva explains
that Incremental Revenues through Incremental Sales (IRIS) unifies retailer and
subscriber recharge processes by providing a seamless, congruent and concurrent
recharge experience to both the parties. IRIS gives the flexibility of treating
each customer and retailer differently and rewards their unique combination at
various levels of the upgrade.
· Asian Paints operations at paints
plant in Rohtak restarts
Asian
Paints operations at its paints plant in Rohtak restarts; operation was closed
for just 10 days – don’t expect any material impact on sales. Asian Paints
operations at its paint Plant situated at Rohtak, Haryana, have restarted. The
unit has manufacturing capacity of 2 lakh kilo litre per annum. Since the
operation were closed from February 22nd 2016, the company loss the production
for just 10 days. We don’t expect it to have any material impact on the sales
and earnings of the company.
· RComm: Disagreement with TPG group
over valuation of tower assets
Reliance
Communications: Disagreement with TPG group over valuation of tower assets,
valued tower assets at Rs15000 crore vs earlier valuation of 21500 crore,
negative read-thru. As per media news, TPG and Tillman Global Holdings LLC have
signalled that they view the assets as worth about Rs15,000 crore, including
debt, after conducting due diligence on Reliance Communications Ltd’s tower
assets, down from the R.21,500 crore proposed earlier in the negotiations.
Reliance Communications said that the bidders have not reduced the enterprise
value for the tower business by that amount
· Cipla: Delays and lack of clarity
are growing concerns
Cipla:
Delays and lack of clarity on launch timeline of inhalers in US market are
growing concerns. Event: Mylan recently announced that its abbreviated new drug
applications (ANDAs) for fluticasone propionate 100, 250, 500mcg and salmeterol
50mcg inhalation powder have been accepted for filing by the US Food and Drug
Administration (USFDA). The USFDA has provided Mylan a goal date of March 28,
2017 (meaning if the product is approved under a standard review period,
generic Advair could be launched in 2017). Mylan has now become the third
generic player to file for generic Advair after Sandoz and Hikma.
Get real time advice for Intraday Trading Tips , Share Market Live , Intraday Equity Tips , Stock Trading tips , Free Intraday Tips , Best Accurate Stock Tips , NSE Stock market Tips and all Maket Updates .
0 comments:
Post a Comment